Elevation Oncology Inc (ELEV) - Total Assets
Based on the latest financial reports, Elevation Oncology Inc (ELEV) holds total assets worth $82.22 Million USD as of March 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Elevation Oncology Inc cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Elevation Oncology Inc - Total Assets Trend (2019–2024)
This chart illustrates how Elevation Oncology Inc's total assets have evolved over time, based on quarterly financial data. See shareholders equity of Elevation Oncology Inc for net asset value and shareholders' equity analysis.
Elevation Oncology Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Elevation Oncology Inc's total assets of $82.22 Million consist of 99.1% current assets and 0.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 51.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Elevation Oncology Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ELEV stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Elevation Oncology Inc's current assets represent 99.1% of total assets in 2024, a decrease from 100.0% in 2019.
- Cash Position: Cash and equivalents constituted 51.7% of total assets in 2024, down from 90.9% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Elevation Oncology Inc Competitors by Total Assets
Key competitors of Elevation Oncology Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
Elevation Oncology Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 19.40 | 46.22 | 11.91 |
| Quick Ratio | 19.40 | 46.22 | 11.91 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $77.96 Million | $105.55 Million | $74.00 Million |
Elevation Oncology Inc - Advanced Valuation Insights
This section examines the relationship between Elevation Oncology Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.46 |
| Latest Market Cap to Assets Ratio | 0.23 |
| Asset Growth Rate (YoY) | 7.3% |
| Total Assets | $95.63 Million |
| Market Capitalization | $21.63 Million USD |
Valuation Analysis
Below Book Valuation: The market values Elevation Oncology Inc's assets below their book value (0.23x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Elevation Oncology Inc's assets grew by 7.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Elevation Oncology Inc (2019–2024)
The table below shows the annual total assets of Elevation Oncology Inc from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $95.63 Million | +7.34% |
| 2023-12-31 | $89.09 Million | -5.38% |
| 2022-12-31 | $94.16 Million | -37.01% |
| 2021-12-31 | $149.49 Million | +84.77% |
| 2020-12-31 | $80.91 Million | +4127.12% |
| 2019-12-31 | $1.91 Million | -- |
About Elevation Oncology Inc
Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. It's lead candidate is EO-3021, an antibody-drug conjugate (ADC) comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 monoclonal antibody (mAb) site-specifically conjugated with a cleavable link… Read more